Isolated Mitochondria Delivery for Targeted Tissue Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mitochondrial damage and dysfunction are lacking, and there is a need for therapeutic, diagnostic, and drug delivery methods utilizing mitochondria.
Innovation Solution
Isolated mitochondria, linked with therapeutic, diagnostic, or imaging agents, are delivered to tissues via injection into blood vessels, allowing for localized or general distribution using simple medical procedures, leveraging their ability to transverse the artery wall and be taken up by cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mitochondria are used as therapeutic agents, then treatment effectiveness is improved, but device complexity increases due to isolation and delivery system requirements
Solution Approach 1:
The patent extracts and isolates mitochondria from cells as a standalone therapeutic unit, removing them from the complex cellular environment. This allows mitochondria to be purified, characterized, and delivered as a discrete therapeutic agent, simplifying the overall treatment system while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent introduces an intermediary delivery system that facilitates the transfer of isolated mitochondria from the isolation chamber to the target tissue. This intermediary system simplifies the complex process of mitochondrial delivery by providing a dedicated transport mechanism that bridges the gap between isolation and therapeutic application.
2Ease of operation
If mitochondria are delivered via blood vessel injection, then ease of operation is improved, but loss of substance increases due to potential leakage or degradation
Solution Approach 1:
The patent performs preliminary stabilization and conditioning of mitochondria before delivery through blood vessels. This preliminary action ensures that mitochondria are prepared in advance to withstand the delivery process and maintain their integrity, reducing loss during transit while allowing for simple intravenous administration.
Solution Approach 2:
The patent incorporates protective measures and stabilization agents that cushion mitochondria against degradation and leakage during blood vessel injection. This beforehand cushioning protects the mitochondria from harmful factors in the circulatory system, maintaining their viability and reducing substance loss while enabling easy intravenous delivery.
3Adaptability or versatility
If combined mitochondrial agents are used, then versatility is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent merges multiple functional components into combined mitochondrial agents, integrating therapeutic, diagnostic, and imaging functions into a single unified agent. This combining approach enhances versatility by allowing one agent to perform multiple functions, while standardization protocols ensure manufacturing precision is maintained through consistent integration methods.
Solution Approach 2:
The patent designs combined mitochondrial agents with universal functionality, creating a single agent that can serve multiple purposes including therapy, diagnosis, and imaging. This multi-functionality approach increases versatility by eliminating the need for separate agents for different purposes, while standardized manufacturing protocols ensure precision is maintained across all functional components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Mitochondria serve as effective carriers for delivering therapeutic, diagnostic, and imaging agents to tissues, avoiding toxicity and immune responses, and providing targeted treatment and imaging capabilities.
Implementation Method 1
after mitochondria are injected or infused, for example, into an artery, the mitochondria can transverse the artery wall and be taken up by cells of the patient's tissues
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3B
AI summary
The disclosure relates to compositions comprising isolated mitochondria or combined mitochondrial agents, and methods of treating disorders using such compositions.